Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Strong Financial Position
Cyclacel's cash equivalents increased to $6 million as of June 2024, compared to $3.4 million at the end of 2023. The company raised $6.3 million through financing activities.
Reduced Net Loss
Net loss for the quarter was reduced to $3.3 million compared to $5.5 million in the same period of 2023.